diabetic patients are expected to develop a lower extremity ulcer during the course of the disease, with foot ulcerations preceding 85% of amputations in diabetic patients. [4] Moreover, 34% of diabetic adults with a diabetic foot ulcer (DFU) develop another ulcer within 1 year of healing of the index wound, and the 5-year rate of new ulcer development is estimated to be as high as 70%. [5] Accordingly, it is reasonable to expect a rapid increase in complications of diabetes as well as significant social and economical burdens as the prevalence of the disease increases.
Blood glucose regulation, removal of necrotic-infected tissues through debridement, offloading, and endovascular or surgical approaches for revascularization and/or reconstruction are used in the management of DFUs. In addition, use of some adjunctive medical therapies and devices is accepted.
One of the well-known adjunctive therapies used in DFU treatment is hyperbaric oxygen therapy (HBOT), in which a patient breathes 100% oxygen intermittently inside a treatment chamber at a pressure higher than sea level pressure. [6] Many randomized trials have emphasized the effect of hyperbaric oxygen as an adjuvant therapy for diabetic foot infections. In these studies, HBOT was shown to increase the rate and reduce the time of healing [7, 8] and decrease the rate of amputation. [9] In negative pressure wound therapy (NPWT), an advanced wound care method, the wound is covered with a sterile sponge or gauze and then vacuumed by delivering negative pressure intermittently or continuously. Although the mechanism of action of NPWT is not clearly understood yet, its rapid and easily observable effects have lead to widespread usage for both acute and chronic wounds. Even though benefits of NPWT on diabetic foot wounds have not been supported in systematical reviews, [10] faster and higher rates of healing, decreased amputation rates, and rapid closure of amputation stumps [11, 12] were shown in a considerable number of randomized controlled trials.
Nevertheless, these present treatment options may fail for a group of patients with an ischemic component, and amputation remains the last option. Thus, new therapies have emerged to promote wound healing and reduce amputation rate in cases of advanced DFU.
Intralesional injection of recombinant human epidermal growth factor (EGF-IL) is a new therapeutic approach. EGF is a polypeptide of 53 amino acids and has been presented as a helpful tool in the treatment of diabetic foot wounds. One of the first identified growth factors, it was primarily isolated from submaxiller saliva glands of mice in the 1960s. EGF-which is released from platelets, macrophages, monocytes, and fibroblastshas autocrine and paracrine effects on epidermal cells, smooth (nonstriated) muscle cells, and fibroblasts. These effects were thought be important for wound healing in leading studies, [13, 14] and EGF is claimed to prevent major amputations in advanced diabetic foot lesions. [15] These presumptions, however, are not clearly supported with scientific research of high evidence levels to date.
In this retrospective case series report, we present our experience of EGF-IL use on selected DFU patients who had advanced ischemia. These patients were offered major amputation as a final option due to insufficient wound healing despite all treatments applied.
Patients and methods
Twelve diabetic foot lesions of 11 diabetic patients (8 males, 3 females; mean age: 62.2±10.6 years) were treated with intradermal EGF injections by the Istanbul Faculty of Medicine Chronic Wound Council between April 2012 and August 2014. Patient selection criteria were as follows: a diabetic patient with chronic foot ulcer, no finding of local infection, and a radiologically proven ischemic limb which was not suitable for revascularization intervention. Results were evaluated retrospectively after a mean period of 14.6 months (range: 2-28 months) following the final injection. The study protocol was approved by the ethical board of the institution. Patients were referred to the Istanbul Faculty of Medicine Chronic Wound Council by other institutions for treatment of DFUs. All patients were diagnosed with type 2 diabetes mellitus and at least 1 concomitant disease and were on insulin therapy. At initial presentation, the average duration of diabetes was 15.7±9.6 years and of the wounds 3.9±2.2 months. Wounds (6 left side, 6 right side) were on a transmetatarsal amputation stump in 9 cases, on the plantar aspect of the heel in 2 cases, and on the foot dorsum in 1. Patient demographics and Wagner, Texas and Perfusion, Extent, Depth, Infection and Sensation (PEDIS) classifications of wounds at initial presentation are given in Table 1 .
All limbs had various degrees of ischemic signs, proven by digital subtraction angiography. At the time of decision-making for EGF treatment, 9 limbs had already undergone either surgical or endovascular interventions for revascularization, but the interventions were either not successful or only effective in the short term. Three patients were not eligible for any type of revascularization procedure. Details of revascularization attempts are given in Table 2 .
All wounds were infected at the time of presenta-tion, proven by wound cultures. Local wound infection was treated with the use of systemic antibiotherapy in all cases. HBOT was applied to 8 patients (30±22 sessions) and NPWT to 8 lesions (9±4 sessions) prior to EGF-IL. NPWT was ceased in 3 lesions because of an increase of size in 2 wounds (patients 3(a) and 11) and intolerable pain in another (patient 7).
On the day of decision-making for EGF-IL treatment, all wounds were free of local infection and were not healing despite the use of appropriate treatment modalities. Lesions were not eligible for plastic surgery reconstruction due to ischemic problems. According to the treatment algorithms of the Istanbul Faculty of Medicine Chronic Wound Council, major amputation was the proposed next step. All treatments prior to EGF-IL injections, details of amputation recommendations, and follow-up data are given in Table 2 .
An average of 12 doses (minimum 6, maximum 25) of EGF-IL 75 μg (Heberprot-P® 75, Heber Biotec, Havana, Cuba) were applied according to manufacturer recommendations. HBOT was given to 9 of 12 lesions, and NWPT was applied to 8 of 12 lesions during and after EGF-IL treatment.
Results
Wound closure was achieved in 10 of 12 feet, by split thickness skin graft in 3 lesions, punch graft in 3, and secondary healing in 4 ( Figure 1 ). A patient who had osteomyelitis at the ankle level (patient 6) wished to discontinue therapy after 6 doses of EGF-IL, and a transtibial amputation was performed. Another patient with transmetatarsal amputation stump ulcer was later diagnosed as having osteomyelitis of the talus and was treated with radical debridement, including talectomy. Although the wound was closed completely, hindfoot reconstruction could not be performed because of vancomycin-resistant infection. The patient underwent aboveknee amputation in another institution. In summary, the limb could be successfully salvaged in 10 of 12 lesions, and the remaining 2 limbs were amputated because of problems not directly related to the wound itself.
Minimal adverse effects of EGF-IL injections such as shivering, yawning, and nausea were observed. Adverse effects did not result in cessation of treatment in any case. No patients complained of pain during injections. Details of adverse effects are given in Table 2 .
Treatment costs vary greatly among countries. Approximate cost of treatment methods in Turkey is listed in Table 3 . Table 2 . Details of revascularization procedures, treatments pre-and post-amputation decision, results, and follow-up period. 
Discussion
Incidence of lower extremity amputation is reported to be 10-16 times higher in diabetic patients. [16] This rate differs throughout the world due to factors such as country of report, definition of diabetes in the country, race, characteristics of the patient population, level of amputation, and types of therapies used. [17] Chronic foot ulcer is one of the etiologies for amputation, while multidisciplinary approach is crucial for ulcer healing and amputation prevention. Along with blood sugar regulation and infection control, offloading, vascular assessment, proper wound care, and application of adjunctive therapies are also necessary. [18] Peripheral arterial disease (PAD) is a well-known risk factor for amputation in patients with diabetic ulcers. [19] The European Study Group on Diabetes and the Lower Extremity (EURODIALE) study, which was conducted in 14 diabetes centers from 10 countries, demonstrated that diabetic ulcers with PAD, when compared to diabetic ulcers without, had a significantly lower healing rate (69% vs 84%), higher amputation rate (8% vs 2%), and higher mortality rate (9% vs 3%). [20] In another study, 185 patients who applied with a new-onset diabetic ulcer were followed for 5 years, and amputation rate was found to be significantly higher in the patients with PAD component-29% in ischemic and 25% in neuroischemic patients, compared to 11% in the neuropathic group. Similarly, 5-year mortality rate of the ischemic group (56%) was found to be higher than that of the neuropathic group (18%). [21] Amputation rates have decreased in accordance with the increase in endovascular and surgical revascularization procedures for ischemic diabetic foot cases. [22] Inan et al. performed distal arterial bypass in 83 diabetic foot cases with Fontaine class III and IV lower extremity ischemia, the results of which indicated that the procedure was beneficial for both short-and long-term wound healing and amputation prevention. Graft patency was 95% at 3-month follow-up and 79% in long-term followup (17.2±7.8 months). Total wound closure was 48%, with 26% of the cases showing a significant improvement in long-term follow-up. [23] Meta-analyses comparing the success of endovascular and surgical procedures showed that the results were similar in terms of both graft patency and limb salvage. [22, 24, 25] In 2006, Acosta et al. applied 25 μgr EGF intralesionally 3 times per week for 8 weeks to 29 patients who were at high risk of amputation due to Wagner 3 or 4 grade lesions with ischemic and/or neuropathic components. Prior to EGF application, all ulcers were followed for 15 or 25 days with sharp debridements and conventional therapy (details of which are not given) but remained refractory. No revascularization was sought or planned for those diagnosed with ischemia. Granulation tissue growth was observed after the eighth application in 86% of patients. After the 24 th application, amputation was avoided in 17 patients (58%). Reepithelization was obtained in 77% of patients, at an average of 66 days. Relapse was seen only in 1 patient at 1-year follow-up. The authors concluded that intralesional EGF application could reduce amputation rates in DFUs. [15] In a multicentered double-blind placebo-controlled Phase III clinical study conducted by Fernández-Montequín et al., intralesional infiltration of 75 μgr and 25 μgr EGF doses and placebo were compared. Both doses were proven to be more effective than placebo, with 75 μgr being significantly more effective than 25 μgr EGF on wound healing. A specific follow-up time with conventional treatments before EGF is not mentioned, and the data presented suggest that ischemic ulcers were not treated since patients potentially needing revascularization were excluded. [26] Velazquez et al. similarly studied the effects of 75 ug EGF on diabetic ulcers. Thirty-two patients with either Wagner grade 3 or 4 ulcers received EGF-IL 3 times per week for 8 weeks. Wound care prior to EGF-IL and vascular assessment of patients were not mentioned, but dressing with saline was applied to the wounds during EGF-IL treatment. Nine of 10 Wagner grade 3 ulcers healed with granulation and full cicatrization, with the remaining patient having to undergo amputation. Twenty of 22 patients' wounds in the grade 4 group experienced total healing, with the remaining 2 patients requiring amputation. Healing rate among all the patients was as high as 91%, and treatment duration was 46.5±8.9 days. [27] In the present study, limb salvage rates and adverse effects are consistent with the results of the Cuban studies. However, there are important differences in our methods, the most significant being patient selection and approach to ischemic wounds. All patients in the present study were assessed for vascular pathology, and revascularization was performed on all eligible patients, whereas in previous studies vascular status was either not taken into account or possibility of revascularization was considered an exclusion criterion. However, for ischemic wounds, evaluation of cases in terms of endovascular or surgical revascularization is a standard approach. Amputation has been avoided in many patients by vascular intervention together with proper wound care. In our study, only patients who failed to heal even after revascularization or were found to be inappropriate for vascular intervention were selected.
In the studies mentioned above, with the exception of Acosta et al., [15] other treatment options prior to EGF-IL application were not implemented. Acosta et al. applied debridement, bed rest, local or systematic antibiotherapy for infection if present, metabolic control, off-loading, and wound care with sterile saline. However, we applied HBOT and NPWT, which are well-known adjuvant therapies extensively used in Turkey for advanced DFUs, along with other treatment options prior to EGF-IL. When compared to EGF-IL infiltrations, these treatment modalities are significantly more costeffective, and their use is supported by stronger evidence.
In the present study, revascularization was the firstchoice treatment, and patients who were deemed appropriate underwent intervention. HBOT and NPWT, along with other standard care procedures, were applied to all patients, but the wounds remained refractory. EGF-IL was applied only in cases where these treatments were not sufficiently effective, and major ampution was the last choice. We believe our results are more significant than those of the Cuban studies in terms of demonstrating EGF-IL' s effects for preventing amputation.
In addition, since many patients healed with revascularization, antibiotherapy, off-loading, wound care, HBOT, and NPWT and did not require EGF-IL in our practice, EGF was applied to a reduced patient population, which is important in terms of cost.
The results of the present study show that intralesional application of EGF can prevent amputations in select complicated DFUs which are nonresponsive to standard care, including HBOT and NPWT. Because of scarce scientific evidence and high costs, EGF-IL should be considered only for ischemic wounds which are not eligible for further revascularization procedures.
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